Drug Profile
Pemvidutide - Altimmune
Alternative Names: ALT-801- Altimmune; SP-1373; VPD-107Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Velocity Pharmaceutical Development
- Developer Altimmune; Velocity Pharmaceutical Development
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis; Obesity
- Phase I Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Preclinical Dyslipidaemias; Hepatic fibrosis